The United States Food and Drug Administration (FDA) has approved Qualitest Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Levetiracetam extended-release tablets, 500mg and 750mg, the generic equivalent of UCB's Keppra XR.

The total combined sales for Levetiracetam extended-release tablets, 500mg and 750mg, in the U.S. for the 12 months ending May 31, 2012, were approximately $124.8 million according to IMS Health.

Qualitest provides affordable, high-quality generic pharmaceuticals. Qualitest is an operating company of Endo Health Solutions Inc., a US-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology.